McClellan: Drug Pricing Reform Under Trump Still Likely, But Not How Dems Propose

November 10, 2016 at 8:19 PM
Despite the defeat of Hillary Clinton and a spike in biopharma stocks after the election of Donald Trump, drug pricing is still likely to be an issue addressed by the incoming administration, although it could take new forms such as putting drug makers at risk under new payment models, former CMS and FDA head Mark McClellan told Inside Health Policy . Drug pricing reform advocates are still hopeful that Trump will tackle drug pricing, noting he previously advocated Medicare price...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.